The global exocrine pancreatic insufficiency (EPI) therapeutics market is expected to grow to USD 2.55 billion by 2026



 The rising geriatric population and the rising prevalence of Exocrine Pancreatic Insufficiency (EPI) is driving demand for therapeutics such as lipase treatment for dietic patients and chymotrypsin and trypsin level optimization, all of which are positively contributing to the growth of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market. Insufficient secretion of pancreatic enzymes like amylase, lipase, and protease, as well as sodium bicarbonate, causes EPI. Several diseases, including various types of diabetes, are linked to an increased risk of exocrine pancreatic insufficiency (EPI).

According to a study published in Current Diabetes Reports, the prevalence of exocrine pancreatic insufficiency (EPI) is higher in people with type 1 diabetes than in people with type 2. As a result, an increase in the number of persons with diabetes is expected to fuel the expansion of the exocrine pancreatic insufficiency (EPI) treatments and diagnostics market.

The global exocrine pancreatic insufficiency (EPI) therapeutics market was worth USD 1.49 billion in 2018 and is expected to grow to USD 2.55 billion by 2026.

Diabetes prevalence and incidence are increasing as a result of sedentary lifestyles and bad diets. According to a study published in Diabetes Research and Clinical In practice, the global diabetes prevalence was 463 million in 2019 and is expected to rise to 578 million by 2030. The demand for innovative treatments is increasing as a result of this. To meet these demands, the market's leading companies are spending in research & development to develop and offer innovative exocrine pancreatic insufficiency therapies, supporting market growth. AzurRx, for example, is developing MS1819, a yeast-derived lipase that has been designed to have higher enzymatic activity than current treatments.

For the historical period 2017–2018 and forecast period 2019–2027, the global exocrine pancreatic insufficiency (EPI) therapeutics market, the rise in prevalence of cystic fibrosis and chronic pancreatitis will exacerbate the growth of the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market. Furthermore, rising diabetes cases are predicted to propel the exocrine pancreatic insufficiency (EPI) therapeutics market forward.

The global exocrine pancreatic insufficiency (EPI)therapeutics market was valued at US$ 3.9 billion in 2018, according to the report, and is expected to grow at a CAGR of 7.2 percent from 2019 to 2027.

Exocrine pancreatic insufficiency is most commonly caused by diabetes. Exocrine pancreatic insufficiency affects about half of cystic fibrosis newborns at birth, and another quarter develops within six months. Exocrine pancreatic insufficiency affects another 15% of people at some point throughout childhood or early adulthood.

As a result, one of the primary drivers driving the exocrine pancreatic insufficiency treatments and diagnostics market is an increase in the global incidence of cystic fibrosis and chronic pancreatitis.

Pancreatic enzyme replacement therapy (PERT) has been extensively explored for exocrine pancreatic insufficiency associated with pancreatic disorders employing pancrelipase products, which are usually purified from the porcine pancreas. For numerous years, pancreatic enzyme preparations have been available as over-the-counter medications in several areas.

However, because of potential side effects and ineffectiveness, certain drug regulatory bodies, such as the US Food and Drug Administration (FDA), have advised producers to get regulatory authorization before marketing their products. Pancrelipase products have been challenging to be approved due to the FDA's strict requirements. As a result, market growth is being slowed.

The global exocrine pancreatic insufficiency (EPI) therapeutics market is dominated by a few key companies.                                                                                                                

  • Allergan plc,
  • AbbVie, Inc.
  •  
  • Nordmark Arzneimittel GmbH & Co. KG is a pharmaceutical company based in Germany.
  •  
  • Digestive Care, Inc. is a company that specializes in digestive health

Comments

Post a Comment

Popular posts from this blog

Quaternary Ammonium Compounds Market to Grow at USD 1.63 billion by 2027: COVID Impact & Post COVID Analysis, Business Opportunities, and Strategies

Image
  By 2027, the global market for Quats (Quaternary Ammonium Compounds) is expected to reach USD 1.63 billion. The market is being driven by the rise in the occurrence of hospital-acquired infections (HAIs) and the implementation of stringent regulations and favorable government initiatives on disinfection and sterilization. Developing economies are expected to give significant opportunities for growth. Fabric softeners, disinfectants, surfactants, antistatic agents, and wood preservation are just a few of the uses for quaternary ammonium compounds. The product's numerous applications are projected to raise demand shortly. Quaternary ammonium compounds are commonly employed as conditioning agents in personal care products, such as skin, textile, and hair softeners. The surfactant industry considers QACs to be the ultimate workhorse. They're on the USEPA's "High Production Volume Chemicals" list. Self-assembly, surface-active properties, detergency, and antibact...
Read more

Butyraldehyde Market Trends, Growth, Demand, opportunities, Scope & Forecast 2027 by CMI

Image
  Buthylaldehyde (also known as butanal) is a 4-carbon aldehyde that is used as a building block in organic syntheses to make various products such as n-butanol, 2-ethyl hexanol, 2-ethyl hexanoic acid, trimethylolpropane, and polyvinyl butyral. Pharmaceuticals, agrochemicals, antioxidants, textile auxiliaries, perfumes, flavors, and many forms of additives are all made with it as an intermediate (fillers, wetting agents, defoaming agents, improvers). Alcohols (mono- and multi-hydroxide), acids, amines, and esters are all made from N-butyraldehyde as a raw material. Rubber accelerators, synthetic resins, plasticizers, solvents, and high molecular weight polymers are the biggest uses of butyraldehyde. All of these buthylaldehyde applications are detailed in this study. Butyraldehyde is widely used as a starting material for the downstream organic synthesis of n-butanol, trimethylolpropane, 2-ethyl hexanoic acid, and polyvinyl butyral. Pharmaceutical intermediates, synthetic resins,...
Read more

Glass Mat Thermoplastic Market : Size, Growth, Regional Analysis, And Market Area

Image
Glass mat thermoplastic is a thermoplastic that can be easily moulded and is used to make a variety of components, primarily in the automotive industry. Because of the longer residual length of the glass strands, glass mat thermoplastic has better mechanical properties than injection moulded reinforced thermoplastic. It is primarily used as a replacement for steel and aluminium. They are available in panel form as well as 3D structural component form. Furthermore, they are a lightweight material with a low relative density, excellent hardness and rigidity at low temperatures, and are chemical and moisture resistant . These are durable materials with ease of recyclability. Furthermore, the demand for the glass mat thermoplastic material from the automobile and aeration industries leads to market growth. When compared to other end-use industries, the automotive application segment is expected to remain the largest. Furthermore, a surge in government initiatives for increased fuel eco...
Read more